PALO ALTO, Calif., Feb. 29, 2016 /PRNewswire/ -- Eiger
BioPharmaceuticals, Inc. announced today plans to participate in
the Cowen & Company 36th Annual Health Care Conference at the
Boston Marriott Copley Place in Boston, Massachusetts.
David Cory, the President and CEO
of Eiger, will present and participate in a question-and-answer
session on March 8, 2016 beginning at
approximately 4:30 p.m. ET.
A live webcast of the presentation and question-and-answer
session will be available on the Eiger BioPharmaceuticals website
at www.eigerbio.com.
A replay of the webcast will be accessible
at www.eigerbio.com beginning approximately one hour
following the completion of the event.
About Eiger
Eiger is a clinical-stage
biopharmaceutical company committed to bringing to market novel
products for the treatment of Orphan diseases. The company
has built a diverse portfolio of well-characterized product
candidates with the potential to address diseases for which the
unmet medical need is high, the biology for treatment is clear, and
for which an effective therapy is urgently needed.
Safe Harbor Statements
In connection with the proposed merger of Celladon Corporation
(Nasdaq: CLDN) and Eiger BioPharmaceuticals, Inc., Celladon has
filed a registration statement on Form S-4 (File No. 333-208521)
with the Securities and Exchange Commission, or the SEC, including
a proxy statement/prospectus/information statement. The
registration statement was declared effective by the SEC on
February 12, 2016. The proxy
statement/prospectus/information statement and any other relevant
documents filed by Celladon with the SEC may be obtained free of
charge at the SEC web site at www.sec.gov. In addition, investors
and security holders may obtain free copies of the documents filed
with the SEC by Celladon by directing a written request to:
Celladon Corporation, 12707 High Bluff Dr #200, San Diego, CA 92130, Attention: Investor
Relations. Investors and security holders are urged to read
the proxy statement/prospectus/information statement and the other
relevant materials before making any voting or investment decision
with respect to the proposed merger.
This communication shall not constitute an offer to sell
or the solicitation of an offer to sell or the solicitation of an
offer to buy any securities, nor shall there be any sale of
securities in any jurisdiction in which such offer, solicitation or
sale would be unlawful prior to registration or qualification under
the securities laws of any such jurisdiction. No offering of
securities in connection with the proposed merger shall be made
except by means of a prospectus meeting the requirements of Section
10 of the Securities Act of 1933, as amended.
Celladon and its directors and executive officers and Eiger and
its directors and executive officers may be deemed to be
participants in the solicitation of proxies from the stockholders
of Celladon in connection with the proposed transaction.
Information regarding the special interests of these directors and
executive officers in the merger is included in the proxy
statement/prospectus/information statement referred to above.
Additional information regarding the directors and executive
officers of Celladon is also included in Celladon Annual Report on
Form 10-K for the year ended December 31, 2014 and the proxy
statement for Celladon's 2015 Annual Meeting of Stockholders. These
documents are available free of charge at the SEC web site at
www.sec.gov and from Investor Relations at Celladon at the address
described above.
Note Regarding Forward-Looking Statements
Statements contained in this press release regarding matters
that are not historical facts are "forward-looking statements"
within the meaning of the Private Securities Litigation Reform Act
of 1995. Such statements include, but are not limited to,
statements relating to the timing and completion of Eiger's
proposed merger with Celladon and the development and potential
benefits of Eiger's product candidates. Because such
statements are subject to risks and uncertainties, actual results
may differ materially from those expressed or implied by such
forward-looking statements. These forward-looking statements are
based upon Celladon's and Eiger's current expectations and involve
assumptions that may never materialize or may prove to be
incorrect. Actual results and the timing of events could differ
materially from those anticipated in such forward-looking
statements as a result of various factors, including the risks
described in the "Risk Factors" section of the proxy
statement/prospectus/information statement referred to above. All
forward-looking statements contained in this press release speak
only as of the date on which they were
made. Eiger undertakes no obligation to update such
statements to reflect events that occur or circumstances that exist
after the date on which they were made.
Investors: Jim Shaffer, Eiger
Bio, Inc., 919-345-4256, jshaffer@eigerbio.com
Logo - http://photos.prnewswire.com/prnh/20151108/285009LOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/eiger-to-participate-in-cowen--company-2016-health-care-conference-300227167.html
SOURCE Eiger BioPharmaceuticals, Inc.